These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 10936933)

  • 1. [Comparison of patterns of drug therapy in Hungary and in developed Western countries for acute coronary syndromes].
    Keltai M
    Orv Hetil; 2000 Jun; 141(26):1449-53. PubMed ID: 10936933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overutilization and underutilization of thrombolysis in routine clinical practice.
    Sleight P
    J Am Coll Cardiol; 2001 May; 37(6):1588-9. PubMed ID: 11345369
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of cholesterol-lowering medications in the United States from 1991 to 1997.
    Siegel D; Lopez J; Meier J
    Am J Med; 2000 Apr; 108(6):496-9. PubMed ID: 10781783
    [No Abstract]   [Full Text] [Related]  

  • 4. Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.
    Wallach-Kildemoes H; Hansen EH
    Eur J Clin Pharmacol; 2015 Oct; 71(10):1245-54. PubMed ID: 26227068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary risk assessment methods and cholesterol lowering.
    Stokoe JM; Jones DW; Beevers DG
    Lancet; 1999 Mar; 353(9158):1097-8. PubMed ID: 10199374
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention.
    Scuffham PA; Kósa J
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):309-17. PubMed ID: 16779529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines.
    Sliz D; Mamcarz A; Filipiak KJ; Siebert J; Naruszewicz M
    Pol Arch Med Wewn; 2010 Sep; 120(9):328-33. PubMed ID: 20864905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of invasive diagnostic techniques and revascularization therapy of acute coronary syndrome in Hungarian and international databases].
    Keltai M; Márkus R; Sitkei E; Zorándi A
    Orv Hetil; 2002 Jan; 143(3):117-22. PubMed ID: 11883108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. East-west differences in reported preventive practices. A comparative study of six European areas of the WHO-CINDI programme.
    Pardell H; Roure E; Drygas W; Morava E; Nüssel E; Puska P; Uhanov M; Laaksonen M; Tresserras R; Saltó E; Salleras L
    Eur J Public Health; 2001 Dec; 11(4):393-6. PubMed ID: 11766479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry.
    Gullón A; Suárez C; Díez-Manglano J; Formiga F; Cepeda JM; Pose A; Camafort M; Castiella J; Rovira E; Mostaza JM;
    Med Clin (Barc); 2017 Mar; 148(5):204-210. PubMed ID: 27993408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing the practice of cardiovascular medicine.
    Braunwald E
    Atheroscler Suppl; 2001 Feb; 2(1):27-30. PubMed ID: 11286153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
    Paragh G; Márk L; Zámolyi K; Pados G; Ofner P
    Clin Drug Investig; 2007; 27(9):647-60. PubMed ID: 17705573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolytic therapy: just do it.
    Fendrick AM
    J Gen Intern Med; 1995 Jun; 10(6):351-2. PubMed ID: 7562128
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey.
    Persell SD; Zei C; Cameron KA; Zielinski M; Lloyd-Jones DM
    Arch Intern Med; 2010 Mar; 170(5):470-7. PubMed ID: 20212185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic therapy a standard practice.
    Hindle H; Norheim J
    Can Fam Physician; 1993 Aug; 39():1724-5. PubMed ID: 8374355
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug prescription rates in secondary cardiovascular prevention in old age: Do vulnerability and severity of the history of cardiovascular disease matter?
    van Peet PG; Gussekloo J; den Elzen WP; Blom JW; de Waal MW; de Ruijter W
    Scand J Prim Health Care; 2015; 33(4):260-8. PubMed ID: 26683286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rural Alberta thrombolysis study. Survey of practice patterns for managing acute myocardial infarction.
    Hindle H; Norheim JK; Renger R
    Can Fam Physician; 1995 Jul; 41():1180-7. PubMed ID: 7647623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy in acute coronary syndromes.
    Sabatine MS; Jang IK
    Acta Cardiol; 1999 Feb; 54(1):3-29. PubMed ID: 10214473
    [No Abstract]   [Full Text] [Related]  

  • 20. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications.
    Leporowski A; Godman B; Kurdi A; MacBride-Stewart S; Ryan M; Hurding S; Do Nascimento RC; Bennie M; Morton A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):655-666. PubMed ID: 30014725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.